scholarly journals Leukocyte-Reduced Platelet-Rich Plasma Treatment of Basal Thumb Arthritis: A Pilot Study

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Markus Loibl ◽  
Siegmund Lang ◽  
Lena-Marie Dendl ◽  
Michael Nerlich ◽  
Peter Angele ◽  
...  
Keyword(s):  
Pilot Study ◽  
Adverse Events ◽  
Plasma Treatment ◽  
Platelet Rich Plasma ◽  
Therapeutic Option ◽  
Dash Score ◽  
Mayo Wrist Score ◽  
Osteoarthritic Joint ◽  
Positive Effect

A positive effect of intra-articular platelet-rich plasma (PRP) injection has been discussed for osteoarthritic joint conditions in the last years. The purpose of this study was to evaluate PRP injection into the trapeziometacarpal (TMC) joint. We report about ten patients with TMC joint osteoarthritis (OA) that were treated with 2 intra-articular PRP injections 4 weeks apart. PRP was produced using the Double Syringe System (Arthrex Inc., Naples, Florida, USA). A total volume of1.47±0.25 mL PRP was injected at the first injection and1.5±0.41 mL at the second injection, depending on the volume capacity of the joint. Patients were evaluated using VAS, strength measures, and the Mayo Wrist score and DASH score after 3 and 6 months. VAS significantly decreased from6.2±1.6to5.4±2.2at six-month follow-up (P<0.05). The DASH score was unaffected; however, the Mayo Wrist score significantly improved from46.5±18.6to67.5±19.0at six-month follow-up (P=0.05). Grip was unaffected, whereas pinch declined from6.02±2.99to3.96±1.77at six-month follow-up (P<0.05). We did not observe adverse events after the injection of PRP, except one occurrence of a palmar wrist ganglion, which resolved without treatment. PRP injection for symptomatic TMC OA is a reasonable therapeutic option in early stages TMC OA and can be performed with little to no morbidity.

scholarly journals The Use of the Oxygenated AirdriveTM Machine Perfusion System in Kidney Graft Preservation: A Clinical Pilot Study

2020 ◽  
Vol 61 (6) ◽  
pp. 153-162
Author(s):  
Julia H.E. Houtzager ◽  
Sebastiaan David Hemelrijk ◽  
Ivo C.J.H. Post ◽  
Mirza M Idu ◽  
Frederike J. Bemelman ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Pilot Study ◽  
Adverse Events ◽  
Deceased Donor ◽  
Kidney Graft ◽  
Machine Perfusion ◽  
End Points ◽  
Viable Solution ◽  
Technical Failures

Background: The shortage of donor kidneys has led to the use of marginal donors, e.g., those whose kidneys are donated after circulatory death. Preservation of the graft by hypothermic machine perfusion (HMP) provides a viable solution to reduce warm ischemic damage. This pilot study was undertaken to assess the feasibility and patient safety of the AirdriveTM HMP system in clinical kidney transplantation. Methods: Five deceased-donor kidneys were preserved using the oxygenated Airdrive HMP system between arrival at the recipient center (Amsterdam UMC) and implantation in the patient. The main study end-points were adverse effects due to the use of Airdrive HMP. Secondary end-points were clinical outcomes and perfusion parameters. All events occurring during the transplantation procedure or within 1 month of follow-up were monitored. Results: Five patients were included in this pilot study. No technical failures were observed during the preservation period using the Airdrive HMP. Mean perfusion parameters were: duration 8.5 h (3–15 h), pressure 25 mm Hg (18–25 mm Hg), flow 49.77 mL/min (19–58 mL/min), resistance 0.57 mm Hg/min/mL (0.34–1.3 mm Hg/min/mL), and temperature 8.2 °C (2–13°C). Mean cold ischemia time (CIT) was 20.2 h (11–29.5 h). No adverse events or technical failures were observed during preservation and transplantation or during the 1-month follow-up. Conclusions: This pilot study showed the feasibility of the use of the Airdrive HMP system with no adverse events in clinical kidney transplantation.

scholarly journals The long-term outcomes of radiosurgery for arteriovenous malformations in pediatric and adolescent populations

2015 ◽  
Vol 16 (2) ◽  
pp. 222-231 ◽  
Author(s):  
Shunya Hanakita ◽  
Tomoyuki Koga ◽  
Masahiro Shin ◽  
Hiroshi Igaki ◽  
Nobuhito Saito
Keyword(s):  
Adverse Events ◽  
Arteriovenous Malformations ◽  
Therapeutic Option ◽  
Long Term Outcomes ◽  
Bleeding Rate ◽  
Study Institute ◽  
Delayed Complications ◽  
Risk Of Hemorrhage

OBJECT Although stereotactic radiosurgery (SRS) has been accepted as a therapeutic option for arteriovenous malformations (AVMs) in children and adolescents, substantial data are still lacking regarding the outcomes of SRS for AVMs in this age group, especially long-term complications. This study aimed to clarify the long-term outcomes of SRS for the treatment of AVM in pediatric patients aged ≤ 18 years. METHODS Outcomes of 116 patients who were aged 4–18 years when they underwent SRS between 1990 and 2009 at the study institute were analyzed retrospectively. RESULTS The median follow-up period after SRS was 100 months, with 6 patients followed up for more than 20 years. Actuarial obliteration rates at 3 and 5 years after SRS were 68% and 88%, respectively. Five hemorrhages occurred in 851 patient-years of follow-up. The annual bleeding rate after SRS before obliteration was calculated as 1.3%, which decreased to 0.2% after obliteration. Shorter maximum nidus diameter (p = 0.02) and higher margin dose (p = 0.03) were associated with a higher obliteration rate. Ten patients experienced adverse events after SRS. Of them, 4 patients presented with delayed complications years after SRS (range 9–20 years after SRS). CONCLUSIONS SRS can reduce the risk of hemorrhage in pediatric and adolescent AVMs, with an acceptable risk of complications in the long term. However, adverse events such as expanding hematoma and radiation necrosis that can occur after substantial follow-up should be taken into account at the time that treatment decisions are made and informed consent is obtained.

Platelet‐rich plasma treatment for melasma: A pilot study

2019 ◽  
Vol 19 (6) ◽  
pp. 1321-1327 ◽  
Author(s):  
Punyaphat Sirithanabadeekul ◽  
Arada Dannarongchai ◽  
Atchima Suwanchinda
Keyword(s):  
Pilot Study ◽  
Plasma Treatment ◽  
Platelet Rich Plasma

scholarly journals Efficacy of azithromycin in the treatment of cutaneous leishmaniasis

2003 ◽  
Vol 36 (1) ◽  
pp. 65-69 ◽  
Author(s):  
Aluízio Prata ◽  
Mario Léon Silva-Vergara ◽  
Laércio Costa ◽  
Ademir Rocha ◽  
Alejandro Krolewiecki ◽  
...  
Keyword(s):  
Pilot Study ◽  
Treatment Failure ◽  
Cutaneous Leishmaniasis ◽  
Adverse Reactions ◽  
Therapeutic Option ◽  
Disease Evolution ◽  
Clinical Control ◽  
Oral Doses ◽  
Open Pilot

The present open pilot study was conducted to assess the efficacy of azithromycin for the treatment of patients with cutaneous leishmaniasis in Araçuaí and Varzelândia, MG. Twenty-four patients with less of six months of disease evolution were treated after clinical examination, Montenegro test and a biopsy. The treatment schemes consisted of oral doses of 500 mg per day for 3, 5 and 10 days and of 1000 mg for two days. A clinical control was performed monthly and treatment cycles were repeated when necessary until full reepithelialization of the lesions. On the occasion of the final evaluation, 20 patients had completed the study and 17 of them (85%) were cured. The time to obtain a cure was 60 days ifor 6 (30%) patients, 90 days for 7 (35%), and 120 for 4 (20%). The three patients with treatment failure received a pentavalent antimonial for 20 days. No adverse reactions to the medication were observed and a 14 month follow-up did not show recurrence in any patient. These results suggest that azithromycin can be a good therapeutic option for the treatment of cutaneous leishmaniasis caused by Leishmania Viannia brasiliensis.

scholarly journals Five-year results of a clinical pilot study utilizing a pedicle-lengthening osteotomy for the treatment of lumbar spinal stenosis

2018 ◽  
Vol 29 (3) ◽  
pp. 241-249 ◽  
Author(s):  
Sergey Mlyavykh ◽  
Steven C. Ludwig ◽  
Christopher K. Kepler ◽  
D. Greg Anderson
Keyword(s):  
Pilot Study ◽  
Adverse Events ◽  
Spinal Stenosis ◽  
Spinal Canal ◽  
Ct Scans ◽  
Time Points ◽  
Lengthening Osteotomy ◽  
Lumbar Spinal ◽  
Disease Specific

OBJECTIVELumbar spinal stenosis (LSS) is a common condition that leads to significant disability, particularly in the elderly. Current therapeutic options have certain drawbacks. This study evaluates the 5-year clinical and radiographic results of a minimally invasive pedicle-lengthening osteotomy (PLO) for symptomatic LSS.METHODSA prospective, single-arm, clinical pilot study was conducted involving 20 patients (mean age 61.7 years) with symptomatic LSS treated by a PLO procedure at 1 or 2 lumbar levels. All patients had symptoms of neurogenic claudication or radiculopathy secondary to LSS, and had not improved after a minimum 6-month course of nonoperative treatment. Eleven patients had a Meyerding grade I degenerative spondylolisthesis in addition to LSS. Clinical outcomes were measured using the Oswestry Disability Index, Zürich Claudication Questionnaire, 12-Item Short Form Health Survey, and a visual analog scale for back and leg pain. Procedural variables, neurological outcomes, adverse events, and radiological imaging (plain radiographs and CT scans) were collected at the 1.5-, 3-, 6-, 9-, 12-, 24-, and 60-month time points.RESULTSThe PLOs were performed through percutaneous incisions, with minimal blood loss in all cases. There were no operative complications. Four adverse events occurred during the follow-up period. Statistically significant improvement was observed in each of the outcome instruments and maintained over the 5-year follow-up period. Imaging studies, reviewed by an independent radiologist, showed no evidence of device subsidence, migration, breakage, or heterotopic ossification. Thin-slice CT scans documented healing of the osteotomy site in all patients at the 6-month time point and an increase of 115% in the mean cross-sectional area of the spinal canal.CONCLUSIONSTreatment of patients with symptomatic LSS with a PLO procedure provided substantial enlargement of the area of the spinal canal and favorable clinical results for both disease-specific and non–disease-specific outcome measures at all follow-up time points out to 5 years. Future research is needed to compare this technique to alternative therapies for LSS.

One-Year Follow-up of Platelet-Rich Plasma Treatment in Chronic Achilles Tendinopathy

2011 ◽  
Vol 39 (8) ◽  
pp. 1623-1630 ◽  
Author(s):  
Suzan de Jonge ◽  
Robert J. de Vos ◽  
Adam Weir ◽  
Hans T. M. van Schie ◽  
Sita M. A. Bierma-Zeinstra ◽  
...  
Keyword(s):  
Plasma Treatment ◽  
Platelet Rich Plasma ◽  
Achilles Tendinopathy ◽  
One Year ◽  
Chronic Achilles Tendinopathy

scholarly journals Functional outcome of platelet rich plasma on lateral epicondylitis of elbow

2017 ◽  
Vol 3 (3) ◽  
pp. 408
Author(s):  
Narayanan V. L. ◽  
Preetha P. ◽  
Maria Joshna J. ◽  
Mishal Dhivya P. J. ◽  
Anbu Selvan
Keyword(s):  
Plasma Treatment ◽  
Conservative Management ◽  
Platelet Rich Plasma ◽  
Lateral Epicondylitis ◽  
Mayo Score ◽  
Plasma Injection ◽  
Before And After ◽  
Elbow Function ◽  
The Mean

<p class="abstract"><strong>Background:</strong> The study was conducted with the aim to explore the efficacy of platelet rich plasma in sixty patients who presented to us with lateral epicondylitis of elbow where conservative management has failed<span lang="EN-IN">.</span></p><p class="abstract"><strong>Methods:</strong> Between 2013 and 2015, 60 patients (M: F- 20: 40) with lateral epicondylitis of elbow were included. All patients presented to us with lateral epicondylitis of elbow where conservative management has failed. All patients are treated with platelet rich plasma injection. Serial follow-up were done at 1, 6 and 12 month.<strong></strong></p><p class="abstract"><strong>Results:</strong> All sixty patients had significant improvement before and after platelet rich plasma injection. The mean VAS score and the Mayo score suggests significant improvement in pain and elbow function following platelet rich plasma treatment<span lang="EN-IN">. </span></p><p class="abstract"><strong>Conclusions:</strong> Platelet rich plasma improves pain and elbow function in patients suffering from lateral epicondylitis where conservative management has failed. Platelet rich plasma treatment may decrease the overall time for healing, and thereby decreasing the overall need for surgical intervention<span lang="EN-IN">.</span></p>

scholarly journals Treatment of subacute/chronic ECU tendinopathy using wrist arthroscopy and open surgical repair

2022 ◽  
Vol 30 (1) ◽  
pp. 230949902110670
Author(s):  
Young-Keun Lee
Keyword(s):  
Surgical Repair ◽  
Clinical Findings ◽  
Wrist Arthroscopy ◽  
Dash Score ◽  
Open Surgical Repair ◽  
Mri Findings ◽  
Open Procedure ◽  
Mayo Wrist Score ◽  
Quick Dash

Purpose To report the arthroscopic and clinical findings of patients with extensor carpi ulnaris (ECU) tendinopathy treated with wrist arthroscopy and open surgical repair. Methods We retrospectively reviewed the medical records of seven patients with chronic ECU tendinopathy who were treated with diagnostic wrist arthroscopy and open surgical repair between 2010 and 2017. Seven cases diagnosed with ECU tendinopathy had undergone open procedure for the ECU tendinopathy, as well as wrist arthroscopy in the same session. Any pathology of the triangular fibrocartilage complex (TFCC) diagnosed by wrist arthroscopy were treated simultaneously with open procedure for the ECU tendinopathy. The functional outcome was evaluated by comparing the preoperative and final follow-up values of range of motion (ROM), grip strength, visual analog scale (VAS) for pain, modified Mayo wrist score and quick disabilities of the arm, shoulder, and hand (DASH) score. Results TFCC tears were identified in four patients of which repair was performed concomitantly. The average follow-up period was 39 months (range, 25–49 months). At the final follow-up, all the outcomes including average VAS score (6.4→1), the ROM (173→192°), quick DASH score (42.5→18.2), and modified Mayo wrist score (48.6→79.3) improved significantly. Conclusion When treating patients with ECU tendinopathy, the possibility of TFCC combined injury should always be considered. If surgical treatment is planned, we suggest a wrist arthroscopy for more accurate diagnosis an intra-articular pathology, particularly for patients whose MRI findings suggest a degenerative tear or degeneration at the periphery of the TFCC. Additionally, if ECU and DRUJ stability is obtained by repair or reconstruction of the concurrent pathologies in the ECU subsheath, TFCC and other intra-articular structures, the results will be favorable.

scholarly journals Platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Jia Zhu Tang ◽  
Ming Jun Nie ◽  
Jian Zhong Zhao ◽  
Guang Cheng Zhang ◽  
Qing Zhang ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Adverse Events ◽  
Knee Osteoarthritis ◽  
Platelet Rich Plasma ◽  
Meta Analysis ◽  
Womac Pain ◽  
Significant Difference ◽  
Vas Scores ◽  
Eq Vas

Abstract Background This study aimed to evaluate the clinical efficacy of platelet-rich plasma (PRP) injection compared with hyaluronic acid (HA) injection for patients undergoing knee osteoarthritis. Methods We systematically searched electronic databases including PubMed, Embase, Web of Science, and the Cochrane Library on January 23, 2020 to identify relevant studies issued in English languages. The outcomes evaluating the efficacy of knee osteoarthritis (KOA) treatment were Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores (WOMAC pain, function, stiffness, and total scores) at 1, 3, 6, and 12 months; International Knee Documentation Committee (IKDC) scores, Lequesne Index score, Visual Analog Scale (VAS) scores, EQ-VAS scores, and KOOS scores. The pooled data were analyzed by Stata 12.0. Results A total of 20 RCTs were enrolled in the present meta-analysis. The pooled results demonstrated that platelet-rich plasma (PRP) injection reduced pain more effectively than hyaluronic acid (HA) injection at 6-month and 12-month follow-up evaluated by WOMAC pain scores and VAS scores. EQ-VAS in the patients treated with PRP injection was lower than that in patients with HA injection at 12 months. Moreover, the patients with PRP injection had a better function recovery than those with HA injection at 1-month, 3-month, 6-month, and 12-month follow-up, as evaluated by WOMAC function scores. WOMAC total scores showed significant difference at 6-month and 12-month follow-up. The IKDC scores indicated PRP injection was significantly more effective than HA injection at 3 months and 6 months. However, the Lequesne Index scores, KOOS scores, and adverse events did not show any significant difference between groups. Conclusion Intra-articular PRP injection appeared to be more efficacious than HA injection for the treatment of KOA in terms of short-term functional recovery. Moreover, PRP injection was superior to HA injection in terms of long-term pain relief and function improvement. In addition, PRP injection did not increase the risk of adverse events compared to HA injection.

Sign in / Sign up

Export Citation Format

Share Document